Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.

When funding is tight, life sciences startups must be even more strategic with requested amounts, timing, and funding sources ...

Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's ...

Building iteration into the product commercialization process can help life sciences companies avoid many of the missteps ...

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

Medical affairs can no longer afford to operate within legacy structures. Enter AI-enabled functional service provider (FSP) models that offer operational relief.

On today's episode of the Business of Biotech, we're speaking with Sara Bonstein, Chief Financial Officer at Insmed, about what it takes to be a successful CFO. Sara provides useful insights on how to ...

To connect the people, ideas, and organizations needed to advance the development of pharmaceuticals, biologics, diagnostics, and medical devices that improve the human condition so that they can be ...

Beyond the focus on the specific value proposition of each new medicine and the actual and perceived pricing pressures on the biopharma industry (which will be at the forefront during the U.S.

Life Science Leader is part of the Life Science Connect network of products and services for life science professionals. Life Science Connect’s vision is to facilitate connections and foster ...